Literature DB >> 34086349

Whole truths but half the blood: Addressing the gap between the evidence and practice of pre-hospital and in-hospital blood product use for trauma resuscitation.

Zain G Hashmi1,2, Mohamad Chehab3, Avery B Nathens4, Bellal Joseph3, Eric A Bank5, Jan O Jansen1,2, John B Holcomb1,2.   

Abstract

BACKGROUND: In recent years, several studies have demonstrated the efficacy of using pre-hospital blood product and in-hospital whole blood for trauma resuscitation. While some observations suggest an encouraging uptake of this evidence by emergency medical service (EMS) agencies and trauma centers, a nationwide characterization of blood product utilization for bleeding trauma patients remains unknown. The objective of this study is to determine nationwide estimates of pre-hospital blood product and in-hospital whole blood utilization for trauma resuscitation. STUDY DESIGN AND METHODS: All adult trauma patients reported to the National Emergency Medical Services Information System (NEMSIS) dataset 2019 were included. Proportions of patients who received any pre-hospital blood product were calculated. The American College of Surgeons (ACS) Trauma Quality Programs (TQP) databases 2015-2017 and first quarter of 2020 were used to calculate the proportion of ACS-verified trauma centers that transfused whole blood.
RESULTS: Among a total of 3,058,804 pre-hospital trauma patients, only 313 (0.01%) received any blood transfusion; 208 (0.21%) patients with systolic blood pressure (SBP) ≤90 mmHg and 121 (0.67%) patients with SBP ≤90 mmHg and heart rate ≥120 beats per minute received any blood product. The proportion of ACS-verified trauma centers transfusing whole blood increased from 16.7% (45/269) in 2015 to 24.5% (123/502) in first quarter of 2020. DISCUSSION: Despite strong evidence and recommendations, pre-hospital utilization of blood products for trauma resuscitation remains low. Additionally, while the overall in-hospital whole blood use also remains low, its use has increased at ACS-verified trauma centers over the past 5 years.
© 2021 AABB.

Entities:  

Year:  2021        PMID: 34086349     DOI: 10.1111/trf.16515

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  5 in total

Review 1.  Emergency Blood Transfusion for Trauma and Perioperative Resuscitation: Standard of Care.

Authors:  Heiko Lier; Dietmar Fries
Journal:  Transfus Med Hemother       Date:  2021-10-29       Impact factor: 3.747

2.  Resuscitation with whole blood or blood components improves survival and lessens the pathophysiological burden of trauma and haemorrhagic shock in a pre-clinical porcine model.

Authors:  Sarah Ann Watts; Jason Edward Smith; Thomas Woolley; Rory Frederick Rickard; Robert Gwyther; Emrys Kirkman
Journal:  Eur J Trauma Emerg Surg       Date:  2022-07-27       Impact factor: 2.374

3.  The Story of Blood for Shock Resuscitation: How the Pendulum Swings.

Authors:  Samuel P Carmichael; Nicholas Lin; Meagan E Evangelista; John B Holcomb
Journal:  J Am Coll Surg       Date:  2021-08-12       Impact factor: 6.532

4.  Multicentre observational study on practice of prehospital management of hypotensive trauma patients: the SPITFIRE study protocol.

Authors:  Marco Tartaglione; Luca Carenzo; Lorenzo Gamberini; Cristian Lupi; Aimone Giugni; Carlo Alberto Mazzoli; Valentina Chiarini; Silvia Cavagna; Davide Allegri; John B Holcomb; David Lockey; Giovanni Sbrana; Giovanni Gordini; Carlo Coniglio
Journal:  BMJ Open       Date:  2022-05-30       Impact factor: 3.006

Review 5.  Hemorrhagic Resuscitation Guided by Viscoelastography in Far-Forward Combat and Austere Civilian Environments: Goal-Directed Whole-Blood and Blood-Component Therapy Far from the Trauma Center.

Authors:  James H Lantry; Phillip Mason; Matthew G Logsdon; Connor M Bunch; Ethan E Peck; Ernest E Moore; Hunter B Moore; Matthew D Neal; Scott G Thomas; Rashid Z Khan; Laura Gillespie; Charles Florance; Josh Korzan; Fletcher R Preuss; Dan Mason; Tarek Saleh; Mathew K Marsee; Stefani Vande Lune; Qamarnisa Ayoub; Dietmar Fries; Mark M Walsh
Journal:  J Clin Med       Date:  2022-01-12       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.